Acute Migraine Treatment with Timolol 0.5% Nasal Spray - Compounding Pharmacists Have an Important Role

Author(s):  Hagan John C III, Kosa Steven C, Chamberlain Tyler

Issue:  Jul/Aug 2024 - Volume 28, Number 4
View All Articles in Issue

Abstract:  For the foreseeable future, timolol 0.5% nasal spray prepared by compounding pharmacists will be the only source for a potentially dramatic new paradigm in the treatment of acute migraine.1 It is also likely other medical conditions can be treated with the compounded timolol nasal spray that need extremely rapid therapeutic beta blocker blood levels when IV infusion is not possible or practical. This manuscript will review the research and development of compounded timolol medication over the past dozen years and reference previous articles in IJPC detailing how the pharmaceutical compounded product is prepared.2 A final goal is to engage physicians in a beneficial working relationship with compounding pharmacies to make immediately available to patients a nasal spray formulation of the beta blocker timolol 0.5% in solution. It has recently been demonstrated for the first time to benefit acute migraine treatment.

Related Categories: PAIN MANAGEMENT

Purchase this article for download in electronic PDF format from IJPC at for $75 at:
https://ijpc.com/Abstracts/Abstract.cfm?ABS=5349

Search the entire IJPC archive by keyword, topic, or issue at:
https://ijpc.com/Products